ClinicalTrials.gg
Status unknownNCT02860429Updated Aug 9, 2016

Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma

A Phase 4 interventional study of Cinobufacini injection and chemotherapy in Gastrointestinal Neoplasms, sponsored by Xiaonan Cui. Status unknown at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-08-09.

Sponsored by Xiaonan Cui · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.

Planned enrollment
43rd of 88
120 · median 120
Started
2016
with 4 others
Phase 4
4 of 110
none open now
Registered
17th of 110
by date
Lead sponsor
3 of 110
Xiaonan Cui

Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 43rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2016, is one of 4 in phase 4, and was the 17th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Gastrointestinal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The clinical trail of Cinobufacini injection combined with Oxaliplatin regimen on gastrointestine carcinoma.This trail is randomized controled.Patients are diagnosed gastrointestinal cancer based on pathology or cell biology.They are randomized into 2 groups:both groups receive Oxaliplatin regimen.The treatment group receives Cinobufotalin 20ml mixed with 5% Glucose injection 500ml from the first day of chemotherapy until seven days in addition to the chemotherapy.The control group only receive the same chemotherapy with the treatment group.Both group have the same adjuvant therapy.Mainly to study of oxaliplatin into Cinobufacini injection leads to the influence of the peripheral nerve toxicity.Clinical evaluation includes neural electrophysiological test,chemotherapy drug toxicities,quality of life(QOL),etc.Blood biochemistry tests mainly include inflammatory cytokines,peroxidase reaction,immune cell number ratio and stress hormone,etc.

03

Conditions studied

  • Gastrointestinal Neoplasms
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age:18-70
  • male and female
  • signed the form.
  • Diagnosis:Gastrointestinal cancer diagnosed by imaging,cell and pathology report.
  • (ECOG)O-2, more than 3 months.
  • Indication for Chemotherapy,no .
  • First time chemotherapy or at least 6 months after last chemotherapy and radiotherapy.
  • At least 8 weeks after last biotherapy.
  • Surgery:had not received transplantation surgery,at least 2 weeks after last major surgery.

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy is .
  • Have the primary disease can cause the neuropathy.
  • A history of other malignant tumor in recent 5 years.
  • Less than 6 months after last chemotherapy or radiotherapy.
  • Less than 8 weeks after last biotherapy.
  • Cinobufotalin allergy.
  • Had received transplantation surgery,less than 2 weeks after last major surgery.
  • Other researchers think is not suitable for this clinical trail.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cinobufacini injection

    Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day. Duration:6 chemotherapy cycles.

    Drug: Cinobufacini injection · Drug: chemotherapy

  • Other
    Control group

    Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.

    Drug: chemotherapy

Interventions

  • DrugHuachansuStudies of HuachansuHuachansu pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.

  • Drugchemotherapy

    Chemotherapy is the oxaliplatin combination with fluorouracil regimen.

06

What researchers measure

Primary outcomes

  1. neural electrophysiological test

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),up to 6 months

Secondary outcomes

  1. The quality of life questionnaire(QLQ)-C30

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  2. National Cancer Institute(NCI)Common Toxicity Criteria

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  3. Levi sensory nerve toxicity classification standard

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  4. image test

    Time frame: For adjuvant chemotherapy patients every 3 months.For saving chemotherapy patients every 2 months.anticipate up to 1 years.

  5. inflammatory cytokines,in blood.

    For example:Interleukin(IL)-6,tumor necrosis factor(TNF)etc,in bood

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  6. peroxidase reaction,in blood.

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  7. immune cell number ratio,in blood.

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

  8. stress hormone,in blood.

    Estradiol(Female),testosterone(male)etc,in bood.

    Time frame: every cycle of chemotherapy(measure 6 cycles,each cycle is 21days),anticipate up to 5 months

07

Study locations

2 sites
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116000, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016 and a primary completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2016
First posted
Aug 9, 2016
Start
Sep 2016
Primary completionEst.
Sep 2017
Last update
Aug 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02860429
Lead sponsor
Xiaonan Cui
Responsible party
Xiaonan Cui (Professor,Chief Physician, The First Affiliated Hospital of Dalian Medical University) — Sponsor-investigator
First posted
Aug 9, 2016
Start date
Sep 2016
Primary completion
Sep 2017 (estimated)
Last update
Aug 9, 2016

Study contacts

Xiaonan Cui, MD,PhD
Contact
cxn23@sina.com
+8618098876725
Rui Zhang
Contact
zzzrrr1234@sina.com
+8613898872185
Xiaonan Cui, MD,PhD
principal investigator · The First Affiliated Hospital of Dalian Medical University
Rui Zhang
principal investigator · Liaoning cancer province

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huachansu

Start the discussion